U.S. Army Medical Research and Development Command

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, U.S. Army Medical Research and Development Command sits in the top decile of US sponsors by registered trial count (#284 of 15,742 sponsors by registered trial count).

77 total trials 3 currently recruiting 71 completed early-phase tilt top decile by trial count

U.S. Army Medical Research and Development Command: 77 sponsored US clinical trials, 3 recruiting.

U.S. Army Medical Research and Development Command sponsors 77 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 71 completed. 0 of these trials are in Phase 3-4 (later-stage) and 70 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Malaria, with 6 trials.

Top-decile sponsor footprint

U.S. Army Medical Research and Development Command ranks in the top decile of sponsors by registered trial count (#284 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

B 83/100

71 of 73 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (97.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

77 total, page 2 of 2

COMPLETED Phase 1

A Study to Determine the Effects of an Investigational Malaria Vaccine Given to Adults Living in the United States and Thereafter to Adults Living in Kenya

NCT00666380

COMPLETED Phase 1

Phase 1 Safety and Immunogenicity of Meningococcal Vaccine

NCT00678652

COMPLETED Phase 1

Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection

NCT00485134

TERMINATED Phase 2

Topical Treatment of Recalcitrant Ulcerative Old World Leishmaniasis With WR 279,396

NCT00657917

COMPLETED Phase 1

NMRC-M3V-Ad-PfCA Vaccine - Clinical Trial 1

NCT00392015

COMPLETED Phase 1

A Study to Determine Whether 2 Investigational Malaria Vaccines Are Safe, Protective Against Malaria in Adults

NCT00385047

COMPLETED Phase 2

Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine

NCT00415051

COMPLETED Phase 1

Study of the Safety of Intravenous Artesunate

NCT00292942

COMPLETED Phase 2

Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults

NCT00350337

COMPLETED Phase 1

Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America

NCT00312663

COMPLETED Phase 1

Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America

NCT00312702

COMPLETED Phase 2

Safety Evaluation of a Q-fever Vaccine, NDBR 105

NCT00584454

COMPLETED Phase 1

Safety and Immunogenicity Study of a Dengue Virus DNA Vaccine

NCT00290147

COMPLETED Phase 1

Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.

NCT00248833

COMPLETED Phase 1

Safety of and Immune Response to a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults

NCT00376090

COMPLETED Phase 2

Comparison of Full-dose Flu Vaccine to Half-dose Flu Vaccine

NCT00283283

COMPLETED Phase 1

Use of Sodium Stibogluconate as a Treatment for Leishmaniasis

NCT00657618

COMPLETED Phase 2

Safety and Immunogenicity Study of a Live Francisella Tularensis Vaccine

NCT00584844

COMPLETED Phase 1

A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine

NCT00412477

COMPLETED Phase 2

Safety and Immunogenicity Study of Rift Valley Fever Vaccine

NCT00584194

COMPLETED Phase 1

Invaplex 50 Vaccine Dose-Ranging

NCT00082069

COMPLETED

Vietnam Head Injury Study - Phase III

NCT00132249

COMPLETED Phase 2

Local Heat Therapy Versus Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis

NCT00884377

COMPLETED Phase 1

Safety and Efficacy Study of RTS,S AS02A/AS01B Vaccine to Prevent Malaria

NCT00075049

COMPLETED Phase 2

Sodium Stibogluconate Treatment of Leishmaniasis

NCT00662012

COMPLETED Phase 1

Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S

NCT01556945

COMPLETED Phase 1

Study of the Safety of Intravenous Artesunate

NCT00292929

← Previous Page 2 of 2

What is open in the U.S. Army Medical Research and Development Command pipeline

3 recruiting of 77 indexed (4% open); 71 completed (92%).

Phase mix: 0 late (III/IV) vs 70 early (I/II) (early-phase heavy).

Top condition: Malaria (6 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

U.S. Army Medical Research and Development Command: open-pipeline peers nationwide

Peers matched on 77 registered trials and 4% open enrollment, not the therapeutic-area sidebar.

U.S. Army Medical Research and Development Command sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400 0%5%10%15%20% Total trials Recruiting share U.S. Army Medical Research and Development CommandUniversity of HawaiiRANDIonis PharmaceuticalsMetroHealth Medical CenterCelgeneMedtronicNeuroAldeyra TherapeuticsDexCom
U.S. Army Medical Research and Development Command sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

U.S. Army Medical Research and Development Command sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 77 trials (± recruiting share)

Sponsors near 4% open enrollment (± trial volume)

What to do with this U.S. Army Medical Research and Development Command page

77 registered trials is a research-attention snapshot, not an endorsement of U.S. Army Medical Research and Development Command or any single study.

  • 3 of U.S. Army Medical Research and Development Command's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Malaria is the condition U.S. Army Medical Research and Development Command studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Malaria trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

U.S. Army Medical Research and Development Command pipeline card: 77 registered trials from official public datasets.Report a data error.